JP4733350B2 - ケモカイン媒介疾患の併用治療 - Google Patents
ケモカイン媒介疾患の併用治療 Download PDFInfo
- Publication number
- JP4733350B2 JP4733350B2 JP2003577881A JP2003577881A JP4733350B2 JP 4733350 B2 JP4733350 B2 JP 4733350B2 JP 2003577881 A JP2003577881 A JP 2003577881A JP 2003577881 A JP2003577881 A JP 2003577881A JP 4733350 B2 JP4733350 B2 JP 4733350B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- alkyl
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(C(C(*)=C1*)=O)=C(*)N1O Chemical compound *C(C(C(*)=C1*)=O)=C(*)N1O 0.000 description 15
- HLPIHRDZBHXTFJ-UHFFFAOYSA-N CCc1ccc[o]1 Chemical compound CCc1ccc[o]1 HLPIHRDZBHXTFJ-UHFFFAOYSA-N 0.000 description 3
- JPBXKQARWDLKOL-HXUWFJFHSA-N CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O Chemical compound CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O JPBXKQARWDLKOL-HXUWFJFHSA-N 0.000 description 1
- OXZGQJVMTYTUMC-LJQANCHMSA-N CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2n[o]c(C)c2)=O)c1O Chemical compound CC(C)[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2n[o]c(C)c2)=O)c1O OXZGQJVMTYTUMC-LJQANCHMSA-N 0.000 description 1
- GSTTYFZPWRSFNV-FQEVSTJZSA-N CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F Chemical compound CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F GSTTYFZPWRSFNV-FQEVSTJZSA-N 0.000 description 1
- RRRRXCOPMMELBR-RGUGMKFQSA-N CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)F Chemical compound CC([C@H](c1cc(C)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)F RRRRXCOPMMELBR-RGUGMKFQSA-N 0.000 description 1
- MVRPGEKCCWFBCK-FQEVSTJZSA-N CC([C@H](c1ccc(C)[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F Chemical compound CC([C@H](c1ccc(C)[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O)(F)F MVRPGEKCCWFBCK-FQEVSTJZSA-N 0.000 description 1
- BGZSEAUPZCITOQ-UHFFFAOYSA-N CCC1=CC=C(C)C1 Chemical compound CCC1=CC=C(C)C1 BGZSEAUPZCITOQ-UHFFFAOYSA-N 0.000 description 1
- WCTGQSUIVKIRPT-OAHLLOKOSA-N CCN(CC)S(c([s]cc1NC(C(C2=O)=O)=C2N[C@H](C(C)C)c2ccc(C)[o]2)c1O)(=O)=O Chemical compound CCN(CC)S(c([s]cc1NC(C(C2=O)=O)=C2N[C@H](C(C)C)c2ccc(C)[o]2)c1O)(=O)=O WCTGQSUIVKIRPT-OAHLLOKOSA-N 0.000 description 1
- DOGFHWZRKIHCNP-MRXNPFEDSA-N CC[C@H](c1cc(CC)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O Chemical compound CC[C@H](c1cc(CC)c[o]1)N(C)C(C(C1=O)=O)=C1Nc1cccc(C(N(C)C)=O)c1O DOGFHWZRKIHCNP-MRXNPFEDSA-N 0.000 description 1
- OHMWIPJDIDNEDU-BZSJEYESSA-N CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)C2=NOC(C)C#C2)=O)c1O Chemical compound CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)C2=NOC(C)C#C2)=O)c1O OHMWIPJDIDNEDU-BZSJEYESSA-N 0.000 description 1
- YXUIAEFAARSCMI-MRXNPFEDSA-N CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O Chemical compound CC[C@H](c1ccc(C)[o]1)NC(C(C1=O)=O)=C1Nc1cccc(C(N(C)c2ccccn2)=O)c1O YXUIAEFAARSCMI-MRXNPFEDSA-N 0.000 description 1
- NZHWONFZYMQAJN-UHFFFAOYSA-N CCc1cc(C(C)C)c[o]1 Chemical compound CCc1cc(C(C)C)c[o]1 NZHWONFZYMQAJN-UHFFFAOYSA-N 0.000 description 1
- SCHTWVSQHFFMTN-UHFFFAOYSA-N CCc1ccc(CSSc2ccccc2)[nH]1 Chemical compound CCc1ccc(CSSc2ccccc2)[nH]1 SCHTWVSQHFFMTN-UHFFFAOYSA-N 0.000 description 1
- XRPDDDRNQJNHLQ-UHFFFAOYSA-N CCc1ccc[nH]1 Chemical compound CCc1ccc[nH]1 XRPDDDRNQJNHLQ-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36531402P | 2002-03-18 | 2002-03-18 | |
| US60/365,314 | 2002-03-18 | ||
| PCT/US2003/008287 WO2003080053A1 (en) | 2002-03-18 | 2003-03-17 | Combination treatments for chemokine-mediated diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533005A JP2005533005A (ja) | 2005-11-04 |
| JP2005533005A5 JP2005533005A5 (https=) | 2010-05-27 |
| JP4733350B2 true JP4733350B2 (ja) | 2011-07-27 |
Family
ID=28454639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577881A Expired - Fee Related JP4733350B2 (ja) | 2002-03-18 | 2003-03-17 | ケモカイン媒介疾患の併用治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20040053953A1 (https=) |
| EP (1) | EP1485089B1 (https=) |
| JP (1) | JP4733350B2 (https=) |
| CN (1) | CN100444839C (https=) |
| AR (1) | AR040400A1 (https=) |
| AU (1) | AU2003220384B2 (https=) |
| BR (1) | BR0308739A (https=) |
| CA (1) | CA2479126C (https=) |
| MX (1) | MXPA04009127A (https=) |
| NO (1) | NO20044402L (https=) |
| NZ (1) | NZ535314A (https=) |
| TW (2) | TW200808314A (https=) |
| WO (1) | WO2003080053A1 (https=) |
| ZA (1) | ZA200407339B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CN1289471C (zh) * | 2001-04-16 | 2006-12-13 | 先灵公司 | 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮 |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| PE20040570A1 (es) | 2002-10-09 | 2004-08-30 | Pharmacopeia Drug Discovery | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina |
| EP1572029B1 (en) * | 2002-11-07 | 2010-03-24 | Abbott Laboratories | Method of loading beneficial agent to a prosthesis by fluid-jet application |
| US8221495B2 (en) * | 2002-11-07 | 2012-07-17 | Abbott Laboratories | Integration of therapeutic agent into a bioerodible medical device |
| US8524148B2 (en) * | 2002-11-07 | 2013-09-03 | Abbott Laboratories | Method of integrating therapeutic agent into a bioerodible medical device |
| DE602004025458D1 (de) | 2003-04-18 | 2010-03-25 | Schering Corp | SYNTHESE VON 2-HYDROXY-N,N-DIMETHYL-3-ii2-i1(R)-(5-METHYL-2-FURANYL)PROPYL AMINO -3,4-DIOXO-1-CYCLOBUTEN-1-YL AMINO BENZAMID |
| ES2308299T3 (es) | 2003-12-19 | 2008-12-01 | Schering Corp | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. |
| TW200530231A (en) * | 2003-12-22 | 2005-09-16 | Schering Corp | Isothiazole dioxides as CXC-and CC-chemokine receptor ligands |
| RU2388756C2 (ru) | 2004-01-30 | 2010-05-10 | Шеринг Корпорейшн | Кристаллические полиморфные формы лиганда схс-хемокинового рецептора |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| CN1997893A (zh) * | 2004-04-16 | 2007-07-11 | 健泰科生物技术公司 | 抗体测定法 |
| CN1984899B (zh) | 2004-05-12 | 2011-07-27 | 先灵公司 | Cxcr1和cxcr2趋化因子拮抗剂 |
| PE20060272A1 (es) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| MX2008000367A (es) | 2005-06-29 | 2008-03-07 | Schering Corp | Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos de receptor de quimiocina en la que dos cisternas son separadas por un solo aminoacido. |
| EP1912971A2 (en) | 2005-06-29 | 2008-04-23 | Shering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| KR20090024248A (ko) | 2006-06-12 | 2009-03-06 | 쉐링 코포레이션 | Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법 |
| WO2008005570A1 (en) * | 2006-07-07 | 2008-01-10 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| EP2155670B1 (en) | 2007-06-06 | 2012-04-18 | Novartis AG | Anti -inflammatory substituted cyclobutenedione compounds |
| CN101932553A (zh) * | 2007-07-03 | 2010-12-29 | 先灵公司 | 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体 |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US20140170112A1 (en) * | 2011-03-12 | 2014-06-19 | Vicus Therapeutics, Llc | Compositions for ameliorating systemic inflammation and methods for making and using them |
| ES2655942T3 (es) | 2011-09-02 | 2018-02-22 | Novartis Ag | Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| KR101306199B1 (ko) * | 2012-01-31 | 2013-09-09 | 부산대학교 산학협력단 | 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물 |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
| MY202326A (en) * | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| EP3737366B1 (en) | 2018-01-08 | 2026-02-25 | ChemoCentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2 |
| SG11202101827RA (en) | 2018-09-21 | 2021-04-29 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors |
| CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| CN121693497A (zh) * | 2023-11-03 | 2026-03-17 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1531943A (fr) | 1966-07-28 | 1968-07-05 | Huels Chemische Werke Ag | Procédé pour stabiliser des poly-acétals macromoléculaires |
| DE1669798A1 (de) | 1966-07-28 | 1971-08-26 | Huels Chemische Werke Ag | Verfahren zum Stabilisieren markomolekularer Polyacetale |
| CS214745B2 (en) * | 1976-08-28 | 1982-05-28 | Huels Chemische Werke Ag | Shaped and non-shaped products from plastic materials |
| DE2638855C3 (de) | 1976-08-28 | 1980-04-24 | Chemische Werke Huels Ag, 4370 Marl | Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe |
| DE3309655A1 (de) | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPS60255756A (ja) * | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| US4978665A (en) | 1987-01-20 | 1990-12-18 | Nissan Chemical Industries Ltd. | 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it |
| JPH02256668A (ja) | 1988-12-20 | 1990-10-17 | Nissan Chem Ind Ltd | ピリダジノン誘導体 |
| US5206252A (en) * | 1992-05-08 | 1993-04-27 | American Home Products Corporation | Thiadiazolyl-amino derivatives of benzopyrans and indanes |
| GB9312210D0 (en) | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| US5506252A (en) * | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| EP0796243B1 (en) | 1994-11-16 | 1999-01-27 | American Home Products Corporation | Diaminocyclobutene-3,4-diones |
| US6300325B1 (en) * | 1997-01-23 | 2001-10-09 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| WO1998033763A1 (en) | 1997-01-30 | 1998-08-06 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
| EP1117633B1 (en) | 1998-10-02 | 2002-09-18 | Neurosearch A/S | Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| AU6111699A (en) | 1998-10-08 | 2000-05-01 | Smithkline Beecham Plc | Novel method and compounds |
| US6376555B1 (en) * | 1998-12-04 | 2002-04-23 | American Home Products Corporation | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers |
| CN1334797A (zh) | 1998-12-14 | 2002-02-06 | 美国家用产品公司 | 抑制经vla－4介导的白细胞粘附的3,4－二氨基－3－环丁烯－1,2－二酮衍生物 |
| DE69927050T2 (de) | 1998-12-16 | 2006-06-29 | Bayer Healthcare Ag | Biphenylverbindungen und biphenyl-analoge als intergrin-antagonisten |
| US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6586446B1 (en) | 1999-10-15 | 2003-07-01 | Bristol-Myers Squibb Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| WO2001064691A1 (en) | 2000-03-01 | 2001-09-07 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| JP2003527360A (ja) | 2000-03-14 | 2003-09-16 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
| CN1454204A (zh) * | 2000-05-30 | 2003-11-05 | 史密丝克莱恩比彻姆公司 | Il－8受体拮抗剂 |
| JP2004520412A (ja) * | 2001-01-16 | 2004-07-08 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体アンタゴニスト |
| DE60216229T2 (de) * | 2001-01-16 | 2007-10-04 | Smithkline Beecham Corp. | Il-8-rezeptorantagonisten |
| US20030204085A1 (en) * | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| WO2002076926A1 (en) * | 2001-02-02 | 2002-10-03 | Schering Corporation | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
| CN1289471C (zh) * | 2001-04-16 | 2006-12-13 | 先灵公司 | 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮 |
| US7132445B2 (en) * | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| JP2005505595A (ja) * | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) * | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| JP4836388B2 (ja) | 2002-03-22 | 2011-12-14 | 第一三共株式会社 | ｅＮＯＳ発現に起因する疾患の予防または治療薬 |
| PE20040570A1 (es) * | 2002-10-09 | 2004-08-30 | Pharmacopeia Drug Discovery | Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina |
-
2003
- 2003-03-17 WO PCT/US2003/008287 patent/WO2003080053A1/en not_active Ceased
- 2003-03-17 CA CA2479126A patent/CA2479126C/en not_active Expired - Fee Related
- 2003-03-17 BR BR0308739-5A patent/BR0308739A/pt not_active IP Right Cessation
- 2003-03-17 AU AU2003220384A patent/AU2003220384B2/en not_active Ceased
- 2003-03-17 US US10/390,078 patent/US20040053953A1/en not_active Abandoned
- 2003-03-17 NZ NZ535314A patent/NZ535314A/en not_active IP Right Cessation
- 2003-03-17 MX MXPA04009127A patent/MXPA04009127A/es unknown
- 2003-03-17 EP EP03716685.7A patent/EP1485089B1/en not_active Expired - Lifetime
- 2003-03-17 JP JP2003577881A patent/JP4733350B2/ja not_active Expired - Fee Related
- 2003-03-17 CN CNB038106183A patent/CN100444839C/zh not_active Expired - Fee Related
- 2003-03-18 TW TW096114061A patent/TW200808314A/zh unknown
- 2003-03-18 TW TW092105892A patent/TW200304811A/zh unknown
- 2003-03-18 AR AR20030100943A patent/AR040400A1/es not_active Application Discontinuation
-
2004
- 2004-09-13 ZA ZA200407339A patent/ZA200407339B/en unknown
- 2004-10-15 NO NO20044402A patent/NO20044402L/no not_active Application Discontinuation
-
2007
- 2007-02-14 US US11/705,929 patent/US7960433B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003080053A1 (en) | 2003-10-02 |
| ZA200407339B (en) | 2005-10-06 |
| NO20044402L (no) | 2004-12-17 |
| US20040053953A1 (en) | 2004-03-18 |
| MXPA04009127A (es) | 2005-01-25 |
| US20070155756A1 (en) | 2007-07-05 |
| NZ535314A (en) | 2007-08-31 |
| AU2003220384B2 (en) | 2007-05-10 |
| US7960433B2 (en) | 2011-06-14 |
| CN1652779A (zh) | 2005-08-10 |
| TW200808314A (en) | 2008-02-16 |
| CN100444839C (zh) | 2008-12-24 |
| CA2479126C (en) | 2011-11-15 |
| AR040400A1 (es) | 2005-04-06 |
| JP2005533005A (ja) | 2005-11-04 |
| EP1485089B1 (en) | 2013-04-17 |
| TW200304811A (en) | 2003-10-16 |
| AU2003220384A1 (en) | 2003-10-08 |
| EP1485089A1 (en) | 2004-12-15 |
| CA2479126A1 (en) | 2003-10-02 |
| BR0308739A (pt) | 2005-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4733350B2 (ja) | ケモカイン媒介疾患の併用治療 | |
| JP6726226B2 (ja) | 複素環式アミンおよびその使用 | |
| ES2835553T3 (es) | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos | |
| JP5490723B2 (ja) | Ｎ−アザ二環式カルボキサミド誘導体、これらの調製およびこれらの治療上の使用 | |
| JP6486002B2 (ja) | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド | |
| TWI537268B (zh) | 流感病毒複製之抑制劑 | |
| JP2009542700A (ja) | Ｃｘｃケモカイン受容体リガンドとしての３，４−ジ置換シクロブテン−１，２−ジオン | |
| AU2017258187A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
| JP2012006982A (ja) | Ｃｘｃｒ１およびｃｘｃｒ２ケモカインアンタゴニスト | |
| WO2014167530A1 (en) | Cannabinoid compounds | |
| JP2005534684A (ja) | Ｃｘｃケモカインレセプタ配位子としての３，４−二置換シクロブテン−１，２−ジオン | |
| SK113998A3 (en) | 6-phenylpyridyl-2-amine derivatives | |
| KR20030008151A (ko) | 이미다조피리딘 및 이미다조피리미딘 항바이러스제 | |
| KR20030004417A (ko) | Ｃｃｒ5 조절제로서의 트리아졸릴 트로판 유도체 | |
| CN102272111A (zh) | 作为大麻素受体配体的1,2-噻唑基衍生物 | |
| MX2008013208A (es) | Derivados de aminometilpiridina, su preparacion y su aplicacion en terapeutica. | |
| KR20240102934A (ko) | 피롤로[2,3-b]피리딘 PGDH 억제제 그리고 제조 및 사용 방법 | |
| JP2016525573A (ja) | ２−［５−［ｎ−（４−フルオロフェニル）カルバモイル］ピリミジン−２−イルスルファニルメチル］−４−（トリフルオロメトキシ）フェニル」ボロン酸 | |
| KR102128810B1 (ko) | 요산 또는 통풍 질환의 예방 또는 치료 | |
| CN117586229A (zh) | 靶向p53突变体的化合物 | |
| CN1830445B (zh) | 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物 | |
| JP2019135244A (ja) | ２−［５−［ｎ−（４−フルオロフェニル）カルバモイル］ピリミジン−２−イルスルファニルメチル］−４−（トリフルオロメトキシ）フェニル」ボロン酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060315 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20091008 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100105 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100408 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110331 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110422 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |